Inhibitory effects of mevastatin and a geranylgeranyl transferase I inhibitor (GGTI-2166) on mononuclear osteoclast formation induced by receptor activator of NFκB ligand (RANKL) or tumor necrosis factor-α (TNF-α)

Biochemical Pharmacology

Volumn 69, Issue 1, 2005, Pages 87-95

  Woo, Je Tae ^a,b   Nakagawa, Hiroshi ^c   Krecic, Annette M ^a   Nagai, Kazuo ^b   Hamilton, Andrew D ^d   Sebti, Said M ^e   Stern, Paula H ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CHUBU UNIVERSITY   (Japan)

^c TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^d YALE UNIVERSITY   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

FTI; Geranylgeranylation; GGTI; Osteoclast differentiation; Small G protein; Statin

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CLOSTRIDIUM DIFFICILE TOXIN B; COLONY STIMULATING FACTOR 1; COMPACTIN; FARNESYL DIPHOSPHATE; FTI 2153; GERANYLGERANIOL; GERANYLGERANYL PYROPHOSPHATE; GERANYLTRANSFERASE; GGTI 2166; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MEVINOLIN; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAC PROTEIN; RHO FACTOR; SIMVASTATIN; TRANSFERASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; MONOCYTE; MONONUCLEAR CELL; MOUSE; NONHUMAN; OSTEOCLAST; PRENYLATION; PRIORITY JOURNAL; STEM CELL;

ALKYL AND ARYL TRANSFERASES; ANIMALS; CARRIER PROTEINS; CELL LINE; ENZYME INHIBITORS; LEUKOCYTES, MONONUCLEAR; LOVASTATIN; MEMBRANE GLYCOPROTEINS; MICE; OSTEOCLASTS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; TUMOR NECROSIS FACTOR-ALPHA;

EID: 9944250487     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.08.036     Document Type: Article

References (39)

1. T. Suda, T. Takahashi, and T.J. Martin Modulation of osteoclast differentiation Endocr Rev 13 1992 66 80
2. T.J. Chambers Regulation of the differentiation and function of osteoclasts J Pathology 192 2000 4 13
3. T. Suda, N. Takahashi, N. Udagawa, E. Jimi, M.T. Gillespie, and T.J. Martin Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families Endocr Rev 20 1999 345 357
4. T. Suda, I. Nakamura, E. Jimi, and N. Takahashi Regulation of osteoclast function J Bone Miner Res 12 1997 869 877
5. A.J. Ridly Rho: theme and variations Curr Biol 6 1996 1256 1264
6. M. Symons Rho family GTPases: the cytoskeleton and beyond Trends Biochem Sci 2 1996 178 181
7. A.J. Self, H.F. Paterson, and A. Hall Different structural organization of Ras and Rho effector domains Oncogene 8 1993 655 661
8. W.W. Stark Jr., M.A. Blaskovich, B.A. Johnson, Y. Qian, A. Vasudevan, and B. Pitt Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells Am J Physiol 275 1998 55 63
9. D. Zhang, N. Udagawa, I. Nakamura, H. Murakami, S. Saito, and K. Yamasaki The small GTP-binding protein, rho p21, is involved in bone resorption by regulating cytoskeletal organization in osteoclasts J Cell Sci 108 1995 2285 2292
10. H. Palokangas, M. Mulari, and H.K. Vaananen Endocytic pathway from the basal plasma membrane to the ruffled border membrane in bone-resorbing osteoclasts J Cell Sci 110 1997 1767 1780
11. S. Razzouk, M. Lieberherr, and G. Cournot Rac-GTPase, osteoclast cytoskeleton and bone resorption Eur J Cell Biol 78 1999 249 255
12. H. Zhao, T. Laitala-Leinonen, V. Parikka, and H.K. Vaananen Down regulation of small GTPase Rab7 impairs osteoclast polarization and bone resorption J Biol Chem 276 2001 39295 39302
13. B.M. Willumsen, A. Christensen, N.L. Hubbert, A.G. Papageorge, and D.R. Lowy The p21 ras C-terminus is required for transformation and membrane association Nature 310 1984 583 586
14. J.F. Hancock, A.I. Magee, J.E. Childs, and C.J. Marshall All ras proteins are polyisoprenylated but only some are palmitoylated Cell 57 1989 1167 1177
15. F.L. Zyang, and P.J. Casey Protein prenylation: molecular mechanisms and functional consequences Annu Rev Bichem 65 1996 241 269
16. F.P. Coxon, M.H. Helfrich, R. Van't Hof, S. Sebti, S.H. Ralston, and A. Hamilton Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298 J Bone Miner Res 15 2000 1467 1476
17. J.E. Fisher, M.J. Rogers, J.M. Halasy, S.P. Luckman, D.E. Hughes, and P.J. Masarachia Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro Proc Natl Acad Sci USA 96 1999 133 138
18. H.L. Benford, N.W. McGowan, M.H. Helfrich, M.E. Nuttall, and M.J. Rogers Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro Bone 28 2001 465 473
19. J. Watanabe, N. Amizuka, T. Noda, and H. Ozawa Cytochemical and ultrastructural examination of apoptotic odontoclasts induced by bisphosphonate administration Cell Tissue Res 301 2000 375 387
20. E. van Beek, E. Pieterman, L. Cohen, C. Lowik, and S. Papapoulos Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates Biochem Biophys Res Commun 264 1999 108 111
21. E. van Beek, C. Lowik, G. van der Pluijm, and S. Papapoulos The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates J Bone Miner Res 14 1999 722 729
22. S.P. Luckman, D.E. Hughes, F.P. Coxon, R. Graham, G. Russell, and M.J. Rogers Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras J Bone Miner Res 13 1998 581 589
23. J.T. Woo, S. Kasai, P.H. Stern, and K. Nagai Compactin suppresses bone resorption by inhibiting the fusion of prefusion osteoclasts and disrupting the actin ring in osteoclasts J Bone Miner Res 15 2000 650 662
24. M.R. Wani, K. Fuller, N.S. Kim, Y. Choi, and T. Chambers Prostaglandin E2 cooperates with TRANCE in osteoclast induction from hemopoietic precursors: synergistic activation of differentiation, cell spreading, and fusion Endocrinology 140 1999 1927 1935
25. N. Takahashi, T. Akatsu, N. Udagawa, T. Sasaki, A. Yamaguchi, and J.M. Moseley Osteoblastic cells are involved in osteoclast formation Endocrinology 123 1988 2600 2602
26. J. Sun, M.A. Blaskovich, D. Knowles, Y. Qian, J. Ohkanda, and R.D. Bailey Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine Cancer Res 59 1999 4919 4949
27. P. Sehr, G. Joseph, H. Genth, I. Just, E. Pick, and K. Aktories ADP ribosylation of rho proteins: effects on nucleotide binding, GTPase activity, and effector coupling Biochemistry 37 1998 5296 5304
28. K. Kobayashi, N. Takahashi, E. Jimi, N. Udagawa, M. Takami, and S. Kotake Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction J Exp Med 191 2000 275 286
29. Y. Azuma, K. Kaji, R. Katogi, S. Takeshita, and A. Kudo Tumor necrosis factor-alpha induces differentiation of and bone resorption J Biol Chem 275 2000 4858 4864
30. H. Ysuda, N. Shima, N. Nakagawa, K. Yamaguchi, M. Kinosaki, and S. Mochizuki Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL Proc Natl Acad Sci USA 95 1998 3597 3602
31. D.L. Lncey, E. Timms, H.L. Tan, M.J. Kelley, C.R. Dunstan, and T. Burgess Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 1998 165 176
32. H. Hsu, D.L. Lacey, C.R. Dunstan, I. Solovyev, A. Colombero, and E. Timms Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand Proc Natl Acad Sci USA 96 1999 3540 3545
33. F.P. Coxon, M.H. Helfrich, B. Larijani, M. Muzylak, J.E. Dunford, and D. Marshall Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages J Biol Chem 276 2001 48213 48222
34. G. Mundy, R. Garrett, S. Harris, J. Chan, D. Chen, and G. Rossini Stimulation of bone formation in vitro and in rodents by statins Science 286 1999 1946 1949
35. C.J. Edwards, D.J. Hart, and T.D. Spector Oral statins and increased bone mineral density in postmenopausal women Lancet 355 2000 2218 2219
36. Y.S. Chung, M.D. Lee, S.K. Lee, H.M. Kim, and L.A. Fitzpatrick HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients J Clin Endocrinol Metab 85 2000 1137 1142
37. C.R. Meier, R.G. Schlienger, M.E. Kraenzlin, B. Schlegel, and H. Jick HMG-CoA reductase inhibitors and the risk of fractures J Am Med Assoc 283 2000 3205 3210
38. K.A. Chan, S.E. Andrade, M. Boles, D.S.M. Buist, G.A. Chase, and J.G. Donahue Inhibitors of hydroxyl-methylglutaryl-coenzyme A reductase and risk of fracture along older women Lancet 355 2000 2185 2188
39. L. Rejnmark, N.H. Buus, P. Vestergaard, F. Andreasen, M.L. Larsen, and L. Mosekilde Statins decrease bone turnover in postmenopausal women: a cross-sectional study Eur J Clin Invest 32 2002 581 589